Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two-Minute sweat test could spot hidden nerve damage

NCT ID NCT04927832

Diagnosis Sponsor: Hôpital Européen Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device called SUDOSCAN, which measures sweat function in just two minutes, to see if it can detect small fiber nerve damage in people with autoimmune diseases (like lupus or rheumatoid arthritis) or unexplained pain. Researchers enrolled 139 adults and compared SUDOSCAN results with standard nerve tests. The goal was to find out how common this nerve damage is and whether SUDOSCAN can help diagnose it non-invasively.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SUDOSCAN device (non-invasive sweat test) and electromyogram (EMG)
What this could lead to
If successful, this could provide a fast, painless way to diagnose small fiber nerve damage earlier in people with autoimmune diseases or chronic pain.
What could go wrong
This is a completed observational study, not a treatment trial. The SUDOSCAN method may not be accurate enough to replace standard nerve tests, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

139 people

The number who actually took part.

Started

Jul 2017

Finished

Feb 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient corresponding to one of the two following groups: 1. Systemic autoimmune pathology known to be complicated by small fiber neuropathies. The following autoimmune pathologies will be included: Lupus, Sjogren, Scleroderma, Myositis, rheumatoid arthritis, Sarcoidosis, Vasculitis of small or medium vessels 2. No conditions known to be responsible at SFN, unexplained pain symptoms * Aged ≥ 18 years * Having given free and informed written consent Exclusion Criteria: * Chronic alcoholism * Unbalanced diabetes * Chemotherapies * HIV * Vitamins B12, B1, B6 deficiencies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myositis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease juvenile dermatomyositis rheumatoid arthritis sarcoidosis Sjogren syndrome systemic lupus erythematosus systemic sclerosis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic autoimmune pathologies Unexplained pain syndrome

Contacts and locations

Locations

  • BENNANI

    Marseille, 13003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.